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Mice depleted for exchange 
proteins Directly Activated by 
cAMp (epac) exhibit irregular liver 
regeneration in response to partial 
hepatectomy
Kathrine Sivertsen Åsrud  1, Line pedersen1, Reidun Aesoy  2, Haruna Muwonge1, 
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Stephen Jenkins4, Rolf Kristian Berge2,5, neil cowan Henderson  4, frode Selheim1,2, 
Stein ove Døskeland1 & Marit Bakke1
The exchange proteins directly activated by cAMP 1 and 2 (Epac1 and Epac2) are expressed in a cell 
specific manner in the liver, but their biological functions in this tissue are poorly understood. The 
current study was undertaken to begin to determine the potential roles of Epac1 and Epac2 in liver 
physiology and disease. Male C57BL/6J mice in which expression of Epac1 and/or Epac2 are deleted, 
were subjected to partial hepatectomy and the regenerating liver was analyzed with regard to lipid 
accumulation, cell replication and protein expression. In response to partial hepatectomy, deletion 
of Epac1 and/or Epac2 led to increased hepatocyte proliferation 36 h post surgery, and the transient 
steatosis observed in wild type mice was virtually absent in mice lacking both Epac1 and Epac2. 
The expression of the protein cytochrome P4504a14, which is implicated in hepatic steatosis and 
fibrosis, was substantially reduced upon deletion of Epac1/2, while a number of factors involved in 
lipid metabolism were significantly decreased. Moreover, the number of Küpffer cells was affected, 
and Epac2 expression was increased in the liver of wild type mice in response to partial hepatectomy, 
further supporting a role for these proteins in liver function. This study establishes hepatic phenotypic 
abnormalities in mice deleted for Epac1/2 for the first time, and introduces Epac1/2 as regulators of 
hepatocyte proliferation and lipid accumulation in the regenerative process.
Diseases related to hepatic steatosis constitute an increasing health problem worldwide. A better understanding 
of the underlying molecular mechanisms in healthy and diseased liver tissue is required for understanding of 
etiology, and for the development of efficient treatment strategies. The second-messenger cAMP is a critical reg-
ulator of hepatic metabolic activity, and was in fact first described due to its effects on glycogenolysis in response 
to glucagon and epinephrine1. cAMP is also a central player in the control of liver lipogenesis2, and has been 
implicated in the transcriptional signaling responses that orchestrate liver regeneration in mammals in response 
to partial hepatectomy (PH)3. In general, the effects of cAMP in the liver have been ascribed to activation of the 
cAMP dependent protein kinase A (PKA), but numerous observations also link the exchange proteins directly 
activated by cAMP (Epac; also known as cAMP-guanine nucleotide exchange factor, cAMP-GEF) to hepatic 
cellular processes4.
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The Epac proteins, Epac1 and Epac2 (hereafter collectively referred to as Epac1/2) are multi-domain proteins 
that function as cAMP-activated exchange factors for the small G-proteins Rap1 and Rap25,6. Epac1/2 are impli-
cated in a wide range of biological processes including glucose stimulated insulin secretion, leptin signaling, 
neuronal growth and differentiation, and memory and learning (reviewed in7). Epac1 and Epac2 are encoded by 
Rapgef3 and Rapgef4, respectively, and differential splicing and alternative promoter usage in combination with 
epigenetic regulation of Rapgef4, give rise to three different Epac2 isoforms, Epac2A, Epac2B and Epac2C8–10. 
Whereas Epac1 is nearly ubiquitously expressed, Epac2 isoforms exhibit a strict tissue specific expression pattern. 
Of particular interest for the current study is that expression of the shortest isoform, Epac2C, is confined to hepat-
ocytes10. Epac2C lacks the N-terminal cyclic nucleotide-binding domain (cNBD-A) found in Epac2A, which is 
required for insulin secretion11, and the Dishwelled-Egl-10-pleckstrin (DEP) domain found in Epac2A, Epac2B 
and in Epac112, that is essential for membrane association11. Overall, the Epac2C isoform has been sparsely stud-
ied. It is known that hepatic stellate cells (HSC) express Epac113, and cholangiocytes, both Epac1 and Epac2A14, 
and in vitro studies link Epac1/2 to hepatic cellular processes, such as formation of canalicular networks15, pro-
liferation of cholangiocytes14 and glucagon-dependent secretion of the fibroblast growth factor 21 (Fgf21) from 
hepatocytes16. In HSC, Epac1 has been implicated in transforming growth factor β1 (TGFβ1) induced signaling13, 
which is believed to integrate pro- and anti-fibrotic signals13,17,18.
However, the functional roles of Epc1/2 in liver have not yet been studied in intact animals, and moreover, 
many of the in vitro studies undertaken to investigate the roles of Epac1/2 in hepatic cells have monitored the 
effects of the cAMP analogue 8-pCPT-2‘-O-Me-cAMP (8-pCPT). Although first described as a specific Epac1/2 
agonist19, it is now clear that 8-pCPT and its derivatives have off target effects20–25, and that it is a rather poor acti-
vator of Epac226. Therefore, to delineate the roles of Epac1/2 in liver physiology we employed mouse models that 
are deleted for Epac1 (Epac1−/−), Epac2 (Epac2−/−; all isoforms), or a combined knockout model of both factors 
(Epac1/2−/−). The mice were subjected to partial hepatectomy (PH), which is widely used to gain insights into 
the mechanisms that control signaling, proliferation and growth in the liver27. We report here that PH provokes 
phenotypes in Epac1/2−/− mice that are related to cell proliferation and lipid turnover in the regenerating liver. 
Moreover, we found that Epac2C expression (mRNA and protein) were increased in response to PH, and compar-
ison of the proteome of wild type (wt) and Epac1/2−/− mice demonstrated altered expression profiles of proteins 
related to hepatic lipid metabolism and disease development.
Results
Liver histology is normal in Epac1−/−, Epac2−/− and Epac1/2−/− mice. Histological analysis 
revealed no apparent abnormalities in liver morphology in Epac1−/−, Epac2−/− or Epac1/2−/− mice (Fig. 1a). 
Moreover, no differences in liver mass were observed in adult mice of the different genotypes, indicating that 
deletion of Epac1/2 does not affect post-natal liver growth (Supplementary Fig. S1). Since Epac1/2 signaling has 
been implicated in bile acid stimulated hepatocyte polarization15, we performed immunohistochemistry (IHC) 
analyses against multidrug resistance protein 1B (ABCB1) to label the apical hepatocyte membrane. The distri-
bution of ABCB1 in wt and Epac1/2−/− mice was indistinguishable (Supplementary Fig. S2a), and canalicular 
length per cell was unaffected by Epac1/2 deletion both pre- and post-PH (Supplementary Fig. S2b). RT-PCR was 
performed to determine the expression of Epac1/2 in different hepatic cells (Fig. 1b). The primer pair used in the 
present study to amplify Epac2 transcripts recognizes all Epac2 isoforms, but we have demonstrated previously, 
Figure 1. Expression of Epac1/2 in liver cells. (a) H&E (20x) staining of liver sections from wt, Epac1−/−, 
Epac2−/− and Epac1/2−/− mice. Bar: 100 μm. (b) RT-PCR of Epac1 and Epac2 mRNA in hepatocytes (Hep), 
liver sinusoidal endothelial cells (LSEC), hepatic stellate cells (HSC), Küpffer cells (KC) and whole liver. −RT: 
without reverse transcriptase.
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both at mRNA and protein level, that the mouse liver only expresses the Epac2C isoform8. Epac1 transcripts were 
identified in sinusoidal endothelial cells, Küpffer (KC) cells and HSC, whereas Epac2C was found solely in hepat-
ocytes (Fig. 1b). Thus, none of the cell types analyzed were found to co-express Epac1 and Epac2.
Deletion of Epac1/2 accelerates DNA replication after PH. To gain insight into the functional roles 
of Epac1/2 in the liver, wt, Epac1−/−, Epac2−/− and Epac1/2−/− mice were subjected to PH and euthanized at four 
post-operative time points (26 h, 36 h, 74 h and 168 h). Mice depleted for Epac1/2 displayed no adverse pheno-
types in response to PH compared to wt mice (i.e. no change in post-operative hepatocellular necrosis or mor-
tality), and the resected liver- to- body weight ratio was similar in all genotypes (Supplementary Fig. S3a), as was 
the restitution of hepatic index (Supplementary Fig. S3b). qPCR was performed to determine whether PH affects 
the expression of Epac1/2 in wt mice. As shown in Fig. 2a, Epac2c mRNA expression in total liver was increased 
at 26 h and 36 h post-PH, but then returned to basal levels. This finding correlates with increased Epac2C pro-
tein expression as determined by proteomic analyses (Supplementary file 2). In contrast, Epac1 mRNA levels 
decreased at 26 h post-PH (Fig. 2b). However, confounding the relevance of this finding is the very low level of 
Epac1 mRNA in total liver (see legend to Fig. 2 for ct-values), as also evident from undetectable levels of Epac1 in 
proteomic analyses of total liver (Supplementary file 2).
To determine whether the proliferative capacity after PH was affected as a consequence of deleting Epac1/2, 
BrdU incorporation in hepatocytes was analyzed to quantify DNA synthesis. In wt mice, BrdU-positive hepat-
ocytes were detectable at 26 h, peaked at 36 h and returned to basal levels 74 h after PH, similar to previously 
reported28. Interestingly, the number of BrdU-positive hepatocytes was substantially increased in Epac1−/−, 
Epac2−/− and Epac1/2−/− mice compared to wt mice 36 h post-PH (Fig. 3a), demonstrating that more hepatocytes 
had entered the S-phase. The increased BrdU incorporation was accompanied by an increased number of DAPI 
stained nuclei per area 36 h post-PH (Fig. 3b). Since the hepatocyte size was similar in wt and Epac1/2−/− mice 
(Supplementary Fig. S3c), these results indicate increased hepatocyte proliferation in Epac1−/−, Epac2−/− and 
Epac1/2−/− mice, and not increased hepatocyte hypertrophy, which is often observed after PH29. The increased 
proliferation of hepatocytes in Epac1/2−/− mice was a result of PH, as DAPI staining revealed similar numbers of 
hepatocytes in resected tissue sections of all genotypes before PH, and because BrdU incorporation was equal in 
response to sham operation in all genotypes (Supplementary Fig. S3d).
Proteomic analyses indicated no changes in the expression of cyclin dependent kinases (Cdks) in Epac1/2−/− 
mice compared to wt mice (Supplementary dataset file 2). We were unable to detect other major cell cycle factors 
Figure 2. The expression of Epac2C mRNA is increased in liver after PH. qPCR analysis of (a) Epac2C and 
(b) Epac1 mRNA in liver pre-PH or 26 h, 36 h, 74 h and 168 h post-PH in wt mice. The CT values for resected 
tissue (4.39 ± 0.12 for Epac2C and 12.29 ± 0.38 for Epac1) were set to 1. Data are expressed as mean ± SD of 
three separate experiments performed in triplicates. One-way ANOVA with Dunnett’s adjustment for multiple 
comparisons was used to determine statistical differences. ***p < 0.001 and ****p < 0.0001: mRNA levels in wt 
livers pre-PH compared to mRNA levels in wt livers at the different postoperative time points (26 h, 36 h, 74 h or 
168 h post-PH). F-statistics (a): F(4,9) = 75.57, p < 0.0001 and (b): F(4,10) = 24.50, p < 0.0001.
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by this method, and therefore performed immunoblotting experiments. The results demonstrated similar levels 
of expression of Cyclin D1 and Cyclin E1 in the different genotypes (Supplementary Fig. S4a–l). In contrast, 
the expression of Interleukin 1 (IL-1), a suppressor of hepatocyte proliferation30, was moderately decreased 
in Epac1−/− mice 26 h post-PH (Supplementary Fig. S4a–d,m–p). Furthermore, the levels of Tumor Necrosis 
Factor alpha (TNFα), a potent pro inflammatory cytokine31, was increased in both Epac1−/− and Epac2−/− 
mice compared to wt mice pre-PH, with a more pronounced increase in Epac1−/− mice (Fig. S4a–d,q–p), and 
down-regulated in Epac1/2−/− mice 36 h post-PH (Fig. S4a–d,q–p) (see Supplementary Fig. S5 for the full- length 
blots).
The regenerating liver of Epac1/2−/− mice display early loss of fat vacuoles. Mice accumulate 
hepatic lipid droplets in response to PH, and this condition of steatosis is particularly evident 20–40 h post-PH32. 
Oil Red O (ORO) staining of the right and caudate lobes that remained after PH revealed extensive lipid accumu-
lation in wt mice at 26 h and 36 h post-PH, followed by a return to basal levels at later time points (Fig. 4). Lipid 
droplets were also observed in Epac1−/−, Epac2−/− and Epac1/2−/− mice 26 h post-PH. The size, shape and distri-
bution of the microvesicular fat vacuoles were comparable in all genotypes at this time point, although quantita-
tive determination of the ORO staining revealed notable individual variations between animals within the same 
experimental group (Fig. 4b). This was especially evident in Epac1/2−/− mice where some individuals exhibited 
moderate steatosis 26 h post-PH, while others presented with a phenotype completely devoid of fat vacuoles 
(Fig. 4b). Of note, all Epac1/2−/− mice presented with a striking absence of fat vacuoles 36 h post-PH (Fig. 4a). 
Reduced fat accumulation was also evident in Epac2−/− mice at both time points (26 h and 36 h post-PH) com-
pared to wt mice (Fig. 4).
Altered lipid profiles and protein expression in the absence of Epac1/2. Plasma lipid profiling 
revealed decreased basal (pre-PH) concentrations of circulating total cholesterol in Epac1−/−, Epac2−/− and 
Epac1/2−/− mice compared to wt mice (Table 1), as previously described in Epac1−/− mice33. The reduction in total 
cholesterol correlated with reduced levels of high-density lipoprotein (HDL) cholesterol, as neither low-density 
lipoprotein (LDL) cholesterol nor unesterified cholesterol levels were changed (Table 1). In accordance with the 
reduced level of HDL cholesterol, circulating phospholipid was also reduced in all Epac1/2 knockout models prior 
to PH. Moreover, the basal levels of triglycerides (TG) was elevated in plasma of Epac1/2−/− mice (Table 1), but 
Figure 3. Increased BrdU-incorporation 36 h post-PH in Epac1−/−, Epac2−/− and Epac1/2−/− mice. (a) BrdU 
incorporation was analyzed in wt, Epac1−/−, Epac2−/− and Epac1/2−/−  mice post-PH for the indicated time 
points. Data is shown as box and whiskers with median and min to max whiskers, n = 2–13 mice/group (6–13 
mice/group at 26 h and 36 h). (b) Quantification of DAPI staining pre-PH, 26 h and 36 h post-PH. Data is shown 
as mean ± SD, n = 3–9 mice/group. Two-way ANOVA with Bonferroni’s adjustment for multiple comparisons 
was used to determine statistical differences between genotypes within each time point. *p < 0.05, ***p < 0.001 
and ****p < 0.0001. F-statistics; (a) F(9,104) = 5.331, p < 0.0001 and (b) F(6,55) = 1.436, p = 0.2176. (a) 
36 h post-PH (mean ± SD): wt: 15.04 ± 6.61; Epac1−/−: 27.97 ± 10.22; Epac2−/−: 36.57± 15.32; Epac1/2−/−: 
34.86 ± 9.37. (b): 36 h post-PH (mean ± SD): wt: 49.6 ± 4.1; Epac1−/−: 57.8 ± 1.9; Epac2−/−: 58.4 ± 2.4; 
Epac1/2−/−: 58.9 ± 3.2.
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the potential significance of this increase is currently unclear. The Epac1/2 knockout models exhibited reduced 
plasma levels of total cholesterol, HDL cholesterol, phospholipids (PL) and TGs, and elevated LDL cholesterol 
levels 36 h post-PH, compared to pre-PH conditions. The wt mice showed a similar profile, although the increase 
Figure 4. Epac1/2−/− mice are devoid of  fat vacuoles 36 h post-PH. ORO staining of sections from livers 
from wt, Epac1−/−, Epac2−/− and Epac1/2−/− mice pre- and post-PH as indicated (20x). (a) Representative 
images of ORO staining. (b) Quantification of ORO-staining. The median and left lateral lobes resected during 
surgery were used as control tissue in these experiments. Data are shown as box and whiskers with median 
and min to max whiskers, n = 4–8 mice/group post-PH and n = 17–23 mice/group pre-PH. Two-way ANOVA 
with Bonferroni’s adjustment for multiple comparisons was used to determine statistical differences between 
genotypes within each time point. *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001. F-statistics: 
F(12,149) = 5.152, p < 0.0001.
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in LDL cholesterol was not significant (Table 1). Of note, Epac1/2−/− mice had a significantly higher level of 
plasma LDL cholesterol than wt and Epac2−/− mice post-PH, indicating increased LDL cholesterol secretion or 
decreased LDL cholesterol uptake in peripheral tissues. The concentration of circulating free fatty acids (FFA) was 
similar before and 36 h after PH in all genotypes (Table 1), demonstrating that the concentration of circulating 
FFA that peaks around 20 h post-PH in mice34, returns to normal also in the absence of Epac1/2.
The hepatic lipid profiles were nearly identical in the different genotypes in mice not subjected to PH (Table 1). 
The only variation found was that Epac1−/− mice had lower levels of phospholipids compared to Epac1/2−/−. 
However, taken together, these results indicate that under resting conditions, lipid metabolism is adequately 
maintained in the absence of Epac1/2. In response to PH, increased hepatic levels of TGs and cholesterol were 
observed in wt mice as reported35. Similarly, cholesterol was significantly increased in Epac1−/− ad Epac2−/− mice 
(Table 1). TG levels were also elevated in these genotypes, but due to large variations between individuals within 
the same genotype (Epac1−/− and Epac2−/−), the differences where not statistically significant. As also evident 
from the ORO staining (Fig. 4), Epac1/2−/− mice exhibited lower levels of TGs in the livers post-PH, but the large 
individual variations within each genotype resulted in non-significant statistical results. In contrast to the other 
genotypes, hepatic cholesterol was not increased in Epac1/2−/− mice after PH, also contributing to an overall 
reduced mass of neutral lipids in this group.
The dramatic effect on lipid accumulation in Epac1/2−/− mice 36 h after PH, but milder effects in mice 
deleted for either Epac1 or Epac2 (Fig. 4 and Table 1), provoked further analyses of the double knockout model. 
Proteomic analyses of liver tissue harvested pre-PH identified 113 proteins that were differentially expressed 
WT Epac1−/− Epac2−/− Epac1/2−/−
Control
Plasma, mmol/l
C 2.75 ± 0.09 2.26 ± 0.21aa 2.25 ± 0.13aa 2.37 ± 0.21aa
HDL-C 2.38 ± 0.03 1.91 ± 0.37aaa 1.99 ± 0.18aa 1.90 ± 0.16aaaa
LDL-C 0.20 ± 0.05 0.21 ± 0.03 0.12 ± 0.04 0.23 ± 0.10
UC 0.80 ± 0.08 0.75 ± 0.06 0.74 ± 0.04 0.78 ± 0.05
TG 1.19 ± 0.33 1.34 ± 0.14 1.44 ± 0.20 1.54 ± 0.31a
NEFA 0.23 ± 0.14 0.017 ± 0.04 0.10 ± 0.13 0.11 ± 0.01
PL 2.99 ± 0.12 2.60 ± 0.03a 2.56 ± 0.16aa 2.69 ± 0.16a
Liver, μmol/g
C 6.35 ± 0.43 7.77 ± 2.09 6.35 ± 0.51 6.69 ± 0.34
TG 5.25 ± 0.91 5.73 ± 0.46 8.86 ± 3.07 5.01 ± 0.50
NEFA 0.61 ± 0.10 0.55 ± 0.08 0.55 ± 0.05 0.55 ± 0.06
PL 21.36 ± 0.76 20.58 ± 0.86dd 21.47 ± 0.69 22.54 ± 0.54
36 h post PH
Plasma, mmol/l
C 1.62 ± 0.17bbbb 1.68 ± 0.17bbb 1.58 ± 0.23bbbb 1.76 ± 0.22bbbb
HDL-C 1.21 ± 0.19bbbb 1.25 ± 0.13bbbb 1.17 ± 0.16bbbb 1.22 ± 0.18bbbb
LDL-C 0.29 ± 0.04ccc 0.41 ± 0.09bb 0.32 ± 0.13bbb, cccc 0.54 ± 0.02bbbb
UC 0.75 ± 0.08 0.70 ± 0.05 0.73 ± 0.08 0.75 ± 0.09
TG 0.68 ± 0.08bbbb 0.65 ± 0.05bbbb 0.57 ± 0.14bbbb 0.54 ± 0.16bbbb
NEFA 0.16 ± 0.11 0.27 ± 0.15 0.23 ± 0.18 0.14 ± 0.07
PL 1.77 ± 0.19bbbb 1.74 ± 0.16bbbb 1.68 ± 0.23bbbb 1.74 ± 0.24bbbb
Liver, μmol/g
C 9.22 ± 0.82bbbb 9.95 ± 0.90bb, c 8.91 ± 1.01bbb 7.81 ± 1.49
TG 78.78 ± 45.62bb 39.47 ± 20.90 56.04 ± 46.97 7.68 ± 1.65
NEFA 1.22 ± 0.41 0.94 ± 0.22 0.98 ± 0.41 0.66 ± 0.10
PL 19.80 ± 1.10bb 19.47 ± 0.91 20.38 ± 0.91 20.24 ± 0.80bbb
Table 1. Altered lipid profile in Epac−/− mice. Enzymatic calorimetric lipid profiling of plasma and liver tissue 
isolated from wild type (wt), Epac1−/−, Epac2−/− and Epac1/2−/− control mice and PH operated mice 36 h 
post surgery. Data are presented as mean ± SD, n = 3–10 mice/group. Two-way ANOVA with Bonferroni’s 
adjustment for multiple comparisons or the non-parametric Kruskal-Wallis test with Dunn’s multiple 
comparison test was used to determine differences between genotypes and treatment groups for each factor. 
ap < 0.05, aap < 0.01, aaap < 0.001 and aaaap < 0.0001: control wt mice compared to control Epac1−/−, Epac2−/− 
and Epac1/2−/− mice. bbp < 0.01, bbbp < 0.001 and bbbbp < 0.0001: control mice compared to PH operated mice 
36 h post surgery, same genotype. cp < 0.05, cccp < 0.001 and ccccp < 0.0001: PH operated Epac1/2−/− mice 36 h 
post surgery compared to PH operated wt, Epac1−/− and Epac2−/− mice 36 h post surgery. ddp < 0.01: control 
Epac1/2−/− mice compared to control wt, Epac1−/− and Epac2−/− mice. F-statistics for lipid profiling in plasma; 
C; F(3,42) = 5.597, p = 0.0025, HDL-C; F(3,41) = 5.777, p = 0.0022, LDL-C; F(3,40) = 4.116, p = 0.0123, 
UC; F(3,42) = 0.2445, p = 0.8647, TG; F(3,42) = 3.995, p = 0.0137, NEFA; F(3,40) = 3.423, p = 0.0261 and 
PL; F(3,41) = 2.368, p = 0.0847. F-statistics for lipid profiling in liver; C; F(3,42) = 1.583, p = 0.2078, TG; 
approximate p < 0.0001, Kruskal-Wallis statistic; 31.21, NEFA; approximate p = 0.0018, Kruskal-Wallis statistic; 
22.85 and PL; F(3,42) = 1.210, p = 0.3177. C: Cholesterol, HDL-C: High-density lipoprotein-cholesterol, LDL-
C: Low-density lipoprotein-cholesterol, UC: unesterified cholesterol, TG: Triglycerides, NEFA: Non-esterified 
fatty acids and PL: phospholipids.
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in Epac1/2−/− mice compared to wt mice (54 increased and 59 decreased). Gene ontology (GO) enrichment 
analyses of the proteins with increased expression pre-PH in Epac1/2−/− mice relative to wt mice indicated 
over-representation of proteins connected to sulfation and sulfotransferase activity, and biosynthetic processes 
related to, among other molecules, cholesterol biosynthesis and steroid metabolism (Fig. 5a; see Supplementary 
Table 1a for an overview of the proteins identified for each GO-term). The proteins with reduced expression in 
Epac1/2−/− mice compared to wt mice pre-PH were mainly associated with lipid metabolism, peroxisome biology 
and oxidation-reduction processes (Fig. 5b, and Supplementary Table 1b). Post-PH, again 113 proteins were dif-
ferentially expressed in Epac1/2−/− mice compared to wt mice (38 increased and 75 decreased). GO enrichment 
analyses of the proteins with decreased expression post-PH predicted enrichment of similar or related pathways 
and processes as before PH, but interestingly, the statistical prediction was considerably strengthened for the 
terms related to peroxisome biology (Fig. 5c; see Supplementary Table 2 for an overview of the proteins identi-
fied for each GO-term). There were no significantly enriched GO-terms for the proteins that were increased in 
Epac1/2−/− mice compared to wt mice post-PH. In accordance with previous studies36, PH altered the hepatic 
protein composition in wt mice, resulting in enrichment of GO terms related to metabolic processes, mainly lipid 
metabolism, the inflammatory response and regeneration (Supplementary Fig. S6). The expression of proteins 
linked to lipid metabolism was also changed in Epac1/2−/− post-PH, and interestingly, the GO analyses predicted 
enrichment for the terms “Negative regulation of gluconeogenesis” and “Very-low density lipoprotein particle” in 
the absence of Epac1/2 (Supplementary Fig. S6).
Of particular interest is that the expression of cytochrome P4504A14 hydroxylase (Cyp4a14) was severely 
affected in Epac1/2−/− mice. This enzyme catalyzes omega-hydroxylation of medium-chain fatty acids, and is 
implicated in hepatic steatosis and fibrosis37. The proteomic analyses demonstrated a 10 and 14 fold repression of 
Cyp4a14 in Epac1/2−/− mice compared to wt mice before and after PH, respectively (Fig. 6a,b). IHC and immu-
noblotting analyses verified the decreased expression of Cyp4A14 in mice deleted for Epac1, Epac2 or Epac1/2 
(Fig. 7 and Supplementary Fig. S7; see Supplementary Fig. S8 for full-length blots). The antibody used in IHC 
and immunoblotting recognizes Cyp4a10 and Cyp4a12, in addition to Cyp4a14. Thus, the IHC and immunob-
lotting results do not perfectly mimic the reduction in Cyp4A14 expression observed in the proteomic analyses. 
Cyp4a12 was downregulated 1.7 fold in Epac1/2−/− mice both before and after hepatectomy (Fig. 6), and Cyp4a10 
was downregulated 2 and 4 fold in Epac1/2−/− mice pre- and post-PH, respectively (Fig. 6). The IHC analyses 
demonstrated that in wt mice, the highest expression of Cyp4A14 was in the centrilobular region38. Epac1−/−, 
Epac2−/− and Epac1/2−/− mice exhibited a distribution pattern with fewer centrilobular Cyp4A14 positive cells, a 
weaker staining intensity and a localization that included Cyp4A14 positive cells in the transition- and periportal 
regions pre-PH (Fig. 7).
Cyp4a14 is a target gene for peroxisome proliferator-activated receptor alpha (PPARα)39, and it is notable that 
a considerable number of the proteins that were differentially expressed in Epac1/2−/− mice compared to wt mice 
(both pre- and post-PH) are known PPARα target genes. In particular, enzymes involved in fatty acid degradation 
were generally decreased in Epac1/2−/− mice as opposed to wt mice (Table 2). However, immunoblotting analyses 
demonstrated no effect on PPARα expression as a consequence of Epac1/2 deletion (Supplementary Fig. S9; see 
Supplementary Fig. S10 for full-length blots) and the proteomic analysis did not provide insight into a potential 
effect of PPARα expression in Epac1/2−/− mice, as we were unable to detect PPARα in this analysis. Cytochrome 
P4507α hydroxylase (Cyp7α1), was the protein found to be most significantly increased in Epac1/2−/− mice 
post-PH compared to before surgery (5-fold) (Fig. 6b). This was in sharp contrast to wt mice where the expression 
of CYP7α1 was decreased in response to PH, in accordance with the literature40 (Supplementary dataset file 2). 
Cyp7α1 is also a PPARα target gene39,41, and catalyzes the first reaction in the bile acid biosynthetic pathway42. 
The expression of other enzymes involved in this process (i.e. Akr1d1: Aldo-keto reductase family 1 member D1 
and HSD17b4: Hydroxysteroid 17-beta dehydrogenase 4) was also altered in Epac1/2−/− mice. Of note is that the 
expression levels of the different PKA subunits (i.e. Prkar1a Prkar2a, Prkaca and Prkacb) were not changed in 
Epac1/2−/− mice (Supplementary dataset file 2), and neither were the expression of the different isoforms of the 
Epac1/2 downstream targets Ras-related protein Rap1/2 (Rap1a, Rap1b, Rap2a:Rap2c;Rap2b). Recently, several 
studied have shown that Epac1/2 is localized to the mitochondria43–46. In this regard, it is interesting to note that 
a substantial number of the proteins with decreased expression in Epac1/2−/− mice that are associated with lipid 
metabolism and oxidation-reduction processes, are mitochondrial proteins (Supplementary Table S3).
The number of KCs is affected in Epac1−/− and Epac2−/− mice. It is intriguing that deletion of either 
Epac1 or Epac2 alone causes phenotypes in response to PH, and that some of the effects are reinforced when both 
factors are deleted. These findings suggest that also Epac1 expressing cells, and not only hepatocytes, are affected 
in the livers of the knockout models. To gain further insights into the potential effects on nonparenchymal cells, 
we quantified the relative numbers of KCs and HSCs by IHC. Both cell types are known to exert stimulatory and 
inhibitory effects on hepatocyte proliferation following PH47,48. We observed no significant differences between 
genotypes with regard to the number of platelet derived growth factor beta (PDGFβ) - positive HSCs (Fig. 8a). 
However, the number of F4/80-positive KCs was increased in Epac1−/− mice pre-PH, and decreased in Epac2−/− 
mice 36 h post-PH (Fig. 8b).
Discussion
The mammalian response to PH has been extensively studied, but the details of how the signaling cascades 
that control liver regeneration integrate, remain incompletely understood. It is known that cAMP and PKA are 
involved, and the production of cAMP is tightly controlled during the process49–52. Moreover, a delay in regener-
ation is observed in mice deleted for the cAMP-regulated transcription factor CREM (cAMP responsive element 
modulator)3. In the present study, we demonstrate for the first time that the cAMP binding proteins Epac1/2 are 
involved in regulating liver regeneration in an in vivo model. Deletion of Epac1 or Epac2, or both factors together, 
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caused phenotypes manifested in increased lipid turnover and DNA synthesis early in the regenerative process. 
Moreover, we found that expression of Epac2C was upregulated in the regenerating liver, that the number of 
KCs cells was altered and that the liver proteome of Epac1/2−/− mice differed from wt mice, a disparity that was 
Figure 5. Functional annotation of differentially expressed proteins. GO enrichment analyses on proteins 
that were differentially expressed in wt and Epac1/2−/− mice (a/b) pre- or (c) 36 h post-PH. (a) Functional 
annotation of proteins with significantly higher expression pre-PH in Epac1/2−/− mice compared to wt. (b) 
Functional annotation of proteins with significantly lower expression pre-PH in Epac1/2−/− mice compared 
to wt. (c) Functional annotation of proteins with significantly lower expression post-PH in Epac1/2−/− mice 
compared to wt. Black bars indicate the respective p-values and grey bars indicate fold enrichment for the 
corresponding GO-term. The number of proteins annotated with each GO-term is shown behind each bar. BP: 
biological processes; MF: molecular function (MF); CC: cellular compartment.
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substantiated in response to PH. Taken together, it appears that loss of Epac1/2 is compatible with normal liver 
functions in mice living in a protected environment, but that these factors become important in the regulation of 
cellular responses in stressful situations. We used global knockout models in this study, and cannot disregard pos-
sible indirect effects of Epac1/2 deletion on liver regeneration, and thus, future analyses to decipher the molecular 
Figure 6. Differentially expressed proteins in Epac1/2−/− mice compared to wt. The proteins that were 
differently expressed in Epac1/2−/− mice compared to wt mice (a) pre- and (b) post-PH are listed. Blue bars 
indicate proteins that were decreased in Epac1/2−/− mice compared to wt mice, and red bars indicate proteins 
that were increased in Epac1/2−/− mice compared to wt mice. Statistics: two-tailed student’s two-sample t-test 
and Z-statistics for FC, only when p < 0.05 for both it was considered significant.
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roles of Epac1 and Epac2 in different hepatic cell lines should include cell-specific knockout models. An example 
of a possible indirect effect is via blood platelets. It is clear that platelets and platelet-derived factors have central 
roles in liver regeneration after PH53–55, and in this regard it is interesting to note that we previously demonstrated 
that Epac1−/− mice (but not Epac2−/− mice) display a bleeding phenotype that is partly caused by altered platelet 
maturation and function56.
Figure 7. Decreased expression of Cyp4A14 in Epac1/2−/− deficient mice. IHC analyses (DAB staining) to 
determine Cyp4a14 expression in liver sections from wt, Epac1−/−, Epac2−/− and Epac1/2−/− mice pre-PH (a–d) 
and 36 h post-PH (e–h). The antibody used also detects Cyp4a10 and Cyp4a12. 4–6 mice in each experimental 
group were analyzed (3 sections from each animal). Representative images are shown. Bar: 200 μm.
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The fact that some of the observed phenotypic traits were substantiated in Epac1/2−/− mice compared to sin-
gle knockouts, indicates that these proteins have distinct, but convergent roles in the regenerative process, and 
that lack of one factor (and both) causes defective cell communication and integration of signals. This notion is 
supported by the cell specific and mutual exclusive expression of Epac1 and Epac2 in the liver, and by the finding 
that the number of Epac1 expressing KCs is altered not only in Epac1−/− mice, but also in Epac2−/− mice post-PH. 
Epac1 exerts anti-inflammatory effects in different biological systems57, and at present, it is unclear whether the 
increased number of F4/80-positive KCs observed in Epac1−/− mice results from increased recruitment of cir-
culating macrophages due to an increased inflammatory state in the absence of Epac1, or caused by intrinsic 
effects of the liver. Interestingly, the pronounced increase in TNFα that we observe in Epac1−/− mice before PH 
is in agreement with an enhanced recruitment of circulating monocyte-derived macrophages, which is known to 
secrete pro-inflammatory cytokines, whereas the pro-regenerative liver resident KCs secrete anti-inflammatory 
cytokines58.
ID Gene symbol Protein name prePH FC postPH FC
P55096 Abcd3 ATP-binding cassette sub-family D member 3 −1.23 −1.19, ns
Q921H8 Acaa1a 3-ketoacyl-CoA thiolase A, peroxisomal −1.51 −1.58
Q8VCH0 Acaa1b 3-ketoacyl-CoA thiolase B, peroxisomal −1.64, ns −2.25
P51174 Acadl Long-chain specific acyl-CoA dehydrogenase, mitochondrial −1.11, ns −1.24
P45952 Acadm Medium-chain specific acyl-CoA dehydrogenase, mitochondrial −1.08, ns −1.25
Q9QYR9 Acot2 Acyl-coenzyme A thioesterase 2, mitochondrial −1.61 −4.18
Q8BWN8 Acot4 Acyl-coenzyme A thioesterase 4 −1.78, ns −1.95
Q9R0H0 Acox1 Peroxisomal acyl-coenzyme A oxidase 1 −1.25 −1.46
P47740 Aldh3a2 Fatty aldehyde dehydrogenase −1.48, ns −2.75
P52825 Cpt2 Carnitine O-palmitoyltransferase 2, mitochondrial −1.02, ns −1.24
P47934 Crat Carnitine O-acetyltransferase −1.59, ns −1.92
O88833 Cyp4a10 Cytochrome P450 4A10 −2.01, ns −3.93
Q91WL5 Cyp4a12a Cytochrome P450 4A12A −1.73 −1.73
O35728 Cyp4a14 Cytochrome P450 4A14 −9.89 −13.73
Q9CQ62 Decr1 2,4-dienoyl-CoA reductase, mitochondrial −1.19, ns −1.31
O35459 Ech1 Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial −1.31 −1.35
Q9DBM2 Ehhadh Peroxisomal bifunctional enzyme; Enoyl-CoA hydratase/3,2-trans-enoyl-CoA isomerase; 3-hydroxyacyl-CoA dehydrogenase −1.18, ns −1.59
P51660 Hsd17b4 Peroxisomal multifunctional enzyme type 2;(3 R)-hydroxyacyl-CoA dehydrogenase; Enoyl-CoA hydratase 2 −1.20 −1.28
Q9Z211 Pex11a Peroxisomal membrane protein 11A −1.99 −2.36
Q9Z2Z6 Slc25a20 Mitochondrial carnitine/acylcarnitine carrier protein −1.01, ns −1.33
Table 2. List of PPARα target genes that are less expressed in Epac1/2−/− mice. PrePH (WTprePH vs. 
Epac1/2−/−prePH), postPH (WTpostPH vs. Epac1/2−/−postPH), negative value: decreased protein expression 
in Epac1/2−/− mice relative to wt mice. ns: not significant. FC: fold change. Please see the Supplementary M&M 
section for details regarding statistical analysis.
Figure 8. Altered KC number in Epac1−/− and Epac2−/− mice. The number of (a) PDGFβ-positive stellate cells 
and (b) F4/80-positive KCs was determined in the livers of wt, Epac1−/−, Epac2−/− and Epac1/2−/− mice pre- 
and 36 h post-PH. Two-way ANOVA with Tukey’s adjustment for multiple comparisons was used to determine 
statistical differences between genotypes within each time point. n = 4–6 mice per group, *p < 0.05, **p < 0.01, 
and ****p < 0.0001. F-statistics: (a) F(3,16) = 2.670, p = 0.0836 and (b) F(3,15) = 6.630, p = 0.0045.
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The discovery that the number of KCs is changed in Epac2−/− mice 36 h post-PH might imply that the 
interaction between hepatocytes and KCs is disturbed. We have limited knowledge of how hepatocyte medi-
ated signaling affects KC replenishment post-PH. However, it has been suggested that dysregulated secretion of 
granulocyte-macrophage colony-stimulating factor (GM-CSF) from hepatocytes interferes with, or delays KC 
replenishment post-PH59,60. This is interesting considering the suggested role for GM-CSF in hepatic lipid home-
ostasis61, and growing evidence demonstrating that KC renewal is affected by the metabolic state of the liver62. It 
is yet to be determined whether GM-CSF mediated signaling is affected in the absence of Epac2C.
Rap1 GTPase, the main downstream Epac1/2 effector, plays an important role in regulating cell proliferation. 
However, the roles of Epac1/2 in cell proliferation have remained elusive, as both pro-mitotic and anti-mitotic 
effects have been ascribed to these proteins depending on cellular context63. The increased BrdU incorporation 
observed in Epac1−/−, Epac2−/− and Epac1/2−/− mice at 36 h post-PH in the present study, indicates that the 
absence of Epac1/2 causes an accelerated first round of hepatocyte proliferation. In mice, coordinated waves of 
hepatocyte proliferation occur in response to PH, with the first round being the most robust64. The expression 
of cell cycle regulators are expressed within hours after PH, and interestingly, it has been demonstrated that 
the relative expression of the different cell cycle components is rather consistent throughout the liver regrowth, 
despite fluctuations in DNA synthesis during the process65. In line with this, although we detected increased pro-
liferation at 36 h post-PH, we did not observe increased expression of Cyclin D1, Cyclin E1or cyclin dependent 
kinases (Cdks) in mice deleted for Epac1/2. However, we can not rule out that the levels of these factors differed 
between wt and Epac1/2 knockout models at time points earlier than 26 h and therefore escaped detection in our 
experimental set-up. We found that the expression of TNFα is lower in Epac1/2−/− mice, and partly in Epac2−/− 
mice compared to wt mice at the peak of DNA-synthesis (36 h post-PH). TNFα triggers the priming phase in 
hepatocyte proliferation after PH, whereas this factor is suppressed at later stages66. Thus, the observed decreased 
expression of TNFα in Epac1/2−/− mice substantiates the idea that hepatocyte proliferation occurs more rapidly 
in mice lacking Epac1/2. Taken together, we suggest that the increased number of BrdU-positive hepatocytes in 
Epac1−/−, Epac2−/− and Epac1/2−/− mice 36 h post-PH, demonstrate that the Epac proteins restrain hepatic cell 
proliferation under normal conditions.
A hallmark of the early stages of liver regeneration in response to PH is the accumulation of lipids, which con-
tributes a greater portion of the energy substrates necessary to complete regrowth67. The finding that Epac1/2−/− 
mice are completely devoid of lipid droplets 36 h post-PH indicates regulatory roles for Epac1/2 in this process 
in wt mice. Despite large individual differences, the ORO-staining at 26 h points to the fact that Epac1/2−/− mice 
were capable of accumulating lipids at early time points after PH. We propose that ablation of Epac1/2 causes a 
shift in the regeneration process with a more rapid lipid turnover accompanied with increased hepatocyte prolif-
eration. These irregularities did affect neither the overall regeneration process nor the survival of the animal, indi-
cating that the role of Epac1/2 is to balance the regulatory mechanisms that control the process. This is consistent 
with several publications demonstrating that normal lipid accumulation in response to PH is not a prerequisite 
for normal regeneration34,68.
The proteomic analyses presented in this study disclosed that the expression of Cyp4A14 is dramatically 
decreased in Epac1/2−/− mice, both pre- and post-PH. This enzyme, and the human homolog (CYP4A hydroxy-
lase), catalyze omega-hydroxylation of medium chain fatty acids and arachidonic acids69. Interestingly, Cyp4A14 
expression is increased in murine models of spontaneous nonalcoholic fatty liver disease (NAFLD)70–72, as well as 
in livers of patients with NAFLD37. Moreover, overexpression of, or genetic ablation of Cyp4A14 in mice corre-
lates with increased and reduced hepatic fat accumulation, respectively, in response to a high fat diet37. The result 
that Cyp4A14 is strongly repressed in livers from Epac1/2−/− mice both before and after hepatectomy provides 
a link between Epac1/2, Cyp4a14 and the regulation of hepatic lipid turnover. NAFLD is displayed as a range 
of diseases that can develop to non-alcoholic steatohepatitis and further to fibrosis73. Cyp4a14 also plays a role 
in the development of fibrosis, as diet induced portal and perisinusoidal fibrosis is attenuated in mice depleted 
for Cyp4A14 expression, as is the expression of fibrosis-related genes in HSC (activation of HSC is central in 
the development of hepatic fibrosis)37. In this context it is of interest that Epac1 has been proposed to exhibit 
anti-fibrotic functions, and that several studies point to Epac1 as an integrator of pro- and anti-fibrotic signals 
in HSC13,17,18. Whereas the pro-fibrogenic factor TGFβ1 decreases Epac1 expression in HSC, overexpression of 
Epac1 inhibits TGFβ1-induced production of collagen13. Expression of Epac1 is also repressed in fibrotic livers 
of mouse and human, and stimulation of Epac1 expression in HSC partly restores carbon tetrachloride induced 
fibrosis in mice17. The effects of high fat feeding in mice deleted for Epac1/2 is not yet clear, as conflicting results 
are obtained from different Epac knockout models23,33,74. A recent study describes increased obesity and fat accu-
mulation in adipose tissue and liver in male mice deleted for Epac2A74. However, since the model used in this 
study74 expresses normal levels of Epac2C in hepatocytes, it does not provide information about the intrinsic roles 
for Epac2C in the liver. On the other hand, it does imply that Epac2A, acting outside of the liver, affects hepatic 
lipid accumulation indirectly, prompting future studies on hepatocyte specific Epac2C knockouts69.
Several mouse models that lack expression of Epac1/2 have been developed23,33,75–78. A common feature of 
these models is that deletion of either Epac1 or Epac2, or both, does not produce gross anatomical or physiolog-
ical abnormalities, but that exposure to stress provokes phenotypes in a diversity of physiological processes, as 
we describe herein for the liver23,33,56,75,76,78–83. Collectively, these studies suggest that Epac1/2 may have evolved 
to balance cellular responses in challenging situations, and implicate Epac1/2 in a number of diseases. Epac1/2 
are considered promising drug targets, and Epac2 has been suggested to be the target for both incretin-related 
drugs and sulfonylureas, which are widely used to treat type 2 diabetes84. Currently, considerable effort is invested 
in developing compounds that specifically act on either Epac1 or Epac2 to tailor treatment and reduce side 
effects26,85. The roles of Epac1/2 in liver physiology disclosed in the present study hold promise for that com-
pounds acting via Epac1/2 may be used in the future to treat liver diseases.
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Materials and Methods
Animals. Male mice (C57BL/6J background, 8–12 weeks) were used in this study. Epac1−/− and Epac2−/− 
mice were generated using the Cre-LoxP targeting strategy described elsewhere56,81–83. Of note, the targeting strat-
egy used ablates the expression of all Epac2 isoforms (i.e. Epac2A, Epc2B and Epac2C). Mice deleted for Epac1 
and Epac2 (Epac1/2−/−) were generated by crossing of Epac1−/− and Epac2−/− mice. Wt mice used in the study 
(originally from Taconic, Denmark) were littermates of Epac1−/− and Epac2−/− mice or, mice bred in the same 
room. The origin of the C57BL/6JBomTac mice is described at https://www.taconic.com/mouse-model/b6jbom. 
The mice were housed in groups of three to five and bred at the animal facility at Haukeland University Hospital 
and maintained under standard conditions with a temperature of 21 °C ± 0.5 °C, humidity of 55% ± 5%, lighting 
of 150 lux and 12 hours light/dark cycle (7 am/7 pm). Animals were housed in IVC II cages with food (RMI (E)) 
and water ab libtium. All animal protocols were approved by the Norwegian Animal Research Authority and per-
formed according to the European Convention for the Protection of Vertebrates Used for Scientific Purposes. The 
Animal Care and Use Programs at University of Bergen are accredited by AAALAC international.
Hepatectomy. 2/3 partial hepatectomy (PH) or sham laparotomy was performed as described86. At the 
selected post-operative endpoints (26 h, 36 h, 74 h and 168 h), the mice were euthanized by CO2- suffocation, 
with administration of BrdU (50 mg/kg IP) 2 h before sacrifice. Tissue removed at time of surgery (left lateral 
and median lobes) and regenerated tissue (right lateral and caudate lobes) removed at selected endpoints were 
flash-frozen on liquid nitrogen, or fixed in 4% paraformaldehyde (PFA; 10x w/v) for 18–24 h, embedded in par-
affin and sectioned (4 μm). Trunk blood was obtained by cardiac puncture, collected into prechilled EDTA-tubes 
and blood plasma prepared. See Supplementary S1 Materials & Methods, for details on H&E, ORO staining, 
hepatocyte size quantification, lipid profiling, immunohistochemistry and immunoblotting.
BrDU analyses. Hepatocyte proliferation was assessed by monitoring BrdU-incorporation on paraffin sec-
tions according to manufacturer’s protocol (Anti-BrdU antibody (BU1/75 (ICR1), ab6326, Abcam)), with some 
modifications: Briefly; paraffin sections were dewaxed and DNA denaturized in HCl (2 N) for 30 min at 37 °C 
followed by neutralization in borate buffer (0.1 M) for 2 × 5 min at RT. Next, sections were rinsed 3 × 5 min in 
TBS, incubated in blocking buffer (10% normal donkey serum/2xTBS-T) for 60 min at RT and incubated with 
Anti-BrdU antibody (1:300 in 3% normal donkey serum/TBS-T) at 4 °C o/n with gentle agitation. Parallel sec-
tions used as negative controls were incubated with Rat IgG2a Isotype Control (1:300 in TBS-T) or in blocking 
buffer o/n at 4 °C. Next, sections were rinsed for 4 × 10 min in 2xTBS and incubated with Alexa Fluor® 488 
Donkey Anti-Rat IgG (1:200 in 3% normal donkey serum/TBS-T) for 1.5 h at RT. Lastly, sections were rinsed 
4 × 10 min in TBS, counterstained and mounted with Prolong® Gold Antifade Reagent with DAPI and cover-
slipped. DAPI-stained sections were not blocked, but directly counterstained and mounted. The stained sec-
tions were visualized with Zeiss Axioplan2 microscope and AxioVision version 4.5 Program (Zeiss), hepatocyte 
proliferation was determined by manually counting positive BrdU nuclear staining. For each mouse, ten 40x 
microscopic fields (in an area of 35.2 mm2) in three different sections were counted blindfolded by two different 
researchers. Likewise, DAPI staining was counted manually in ten 40x microscopic fields in one section from 
each mouse.
Real time (RT) and quantitative (q) PCR. Primary cell isolation and fluorescence-activated cell sort-
ing. Hepatocytes and HSC were isolated as described previously8,87. Liver resident macrophages (KCs) were 
extracted as described previously88. In brief, mouse liver was perfused through the inferior vena cava with PBS. 
Livers were excised, minced and digested in solution I (0.8 mg/ml collagenase V, 0.625 mg/ml collagenase D, 
1 mg/ml Dispase and 30 μg/ml DNase). The suspension was shaken on an orbital shaker at 37 °C for 25 min, with 
additional vigorous manual shaking every 5 min. Digest was strained through a 100 μm cell strainer. Following 
2 × 5 min centrifugation at 300 g RBC lysis buffer was added for 3 min to lyse red blood cells. Cells were then 
centrifuged at 300 g for 5 min, resuspended in FACS buffer (2% FBS (Gibco) and 2 mM EDTA in Dulbecco’s 
phosphate-buffered saline no calcium, no magnesium (Gibco)) and filtered through a 35 μm strainer. Cells were 
blocked with 10% mouse serum (Sigma) containing 1% Purified anti-mouse CD16/32 (Biolegend) for 10 min. 
Cells were then incubated with fluorescent conjugated antibodies (FITC anti-mouse CD45.2, PE/Cy7 anti-mouse 
F4/80, APC/Cy7 anti-mouse/human CD11b, PE anti-mouse CD3, PE anti-mouse CD19, PE anti-mouse Ly-6G, 
APC anti-mouse CD31 and PE Rat Anti-Mouse Siglec-F) or isotype control at 4 °C for 30 min in the dark. Cells 
were washed, resuspended in FACS buffer and sorted using a FACS Aria II (BD Biosciences, USA). Following a 
positive CD45.2 gate and dump of CD3, CD19, Ly-6G, Siglec-F, and CD31 positive KCs were defined as the F4/80 
high, CD11b intermediate population.
To isolate liver sinusoidal endothelial cells (LSEC), mouse liver was perfused through the inferior vena cava 
with PBS. Livers were excised, minced and digested in a solution containing 5 mg/ml collagenase I and 11μg/ml 
DNase. This cell suspension was shaken at 37 °C for 20 min. Digest was strained through a 70 μm cell strainer. 
Following 7 min centrifugation at 400 g, RBC Lysis buffer was added for 5 min. Cells were then centrifuged at 
400 g for 7 min, resuspended in FACS buffer and filtered through a 35 μm strainer. Cells were blocked with 10% 
mouse serum and 1% CD16/32 for 10 min. Cells were then incubated with fluorescent conjugated antibodies (PE/
Cy7 anti-mouse CD45 and APC anti-mouse CD31 clone. 390) or isotype control at 4 °C for 30 min in the dark. 
Cells were washed, resuspended in FACS buffer and sorted using a FACS Aria II. Endothelial cells were sorted 
from the CD31 positive, CD45 negative population.
RNA was extracted from the isolated cells using the RNeasy Micro kit (74004, Qiagen, Germany), and 
converted to cDNA using the SuperScript® III First-Strand Synthesis SuperMix for qRT-PCR kit (Invitrogen, 
Waltham, MA, USA). The RT-PCR reaction was carried out as described in8. For qPCR analyses, RNA was pre-
pared from total liver and converted to cDNA using the GenElute Mammalian Total RNA miniprep Kit, and 
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the iScript™ cDNA Synthesis kit (BioRad). qPCR was carried out on a LightCycler 480 II (Roche) using SYBR 
Green Supermix (BioRad) with following amendments in the thermal cycling protocol: 1 cycle for 300 sec at 
95 °C and 40 cycles for 10 sec at 95 °C, 10 sec at 59 °C and 10 sec at 72 °C followed by a melting curve analysis. All 
samples were run in triplicates and repeated in three separate experiments. Expression levels of Epac1 and Epac2 
Universal were normalized to the geometrical mean of SDHA and Ppib, and relative gene expression determined 
using the 2−ΔΔCt-method89–91. Primer sequences: Epac1 fwd: GAAAATGGCTGTGGGAACGTATCT, Epac1 rev: 
AGCTGCTCAGGGTGTGGGGT, Epac2 Universal fwd: ATCTACGAGACGAGCT CCTTCATATTAAA, Epac2 
Universal rev: GACTACATTCACGGATCCTTTCAGA, β-Actin fwd: GGCCCAGAGCAAGAGAGGTATC, 
β-Actin rev: AGGCATACAGG GACAGCACAGC, Ppib fwd: GGAGATGGCACAGGAGGAAA, Ppib rev: 
CGTAG TGCTTCAGCTTGAAGTTCT, SDHA fwd: CATGCCAGGGAAGATTACAA and SDHA rev: 
GCACAGTCAGCCTCATTCAA.
Proteomic analyses. Frozen liver samples (10–12 µg) harvested pre- and 36 h post-PH were lysed in SDS 
lysis buffer (4% SDS in 0.1 M Tris-HCl, pH 7.6) and processed for LC-MS analysis according to the filter-aided 
sample preparation (FASP) procedure92, as described93. NanoLC mass spectrometry and proteomic data analy-
ses were performed as described in Supplementary Materials & Methods. Proteins with significant differential 
expression were classified according to their biological processes using Gene ontology (GO) enrichment analysis 
with the online resource A.GO.TOOL software (University of Copenhagen, Denmark)94.
Statistics. Statistical analysis was performed using GraphPad Prism 6.0. The One-way ANOVA with 
Dunnett’s or Bonferroni’s adjustment for multiple comparisons (when applicable) or the Two-way ANOVA with 
Bonferroni’s adjustment for multiple comparisons (when applicable) was used to assess statistical differences 
between groups. The Brow-Forsynthe test was used to test the normality of the data. If the data did not meet the 
requirements for normal distribution, the non-parametric Kruskal-Wallis test with Dunn’s multiple compar-
ison was used to assess statistical differences between groups. The data are shown as median with and min to 
max whiskers for box plots and mean ± SD for others. The degrees of freedom, F- and p-values for the different 
pair-wise comparisons are also provided in the figure legends. p < 0.05 was considered statistically significant. 
Proteomics: See Supplementary Materials & Methods.
Data Availability
The proteomics raw files and data were uploaded to the ProteomeXchange consortium (version 2.3.0) via the 
PRIDE partner repository, and with the dataset identifier PXD00616595,96. A detailed description of the LC-MS 
analysis is provided in the Supplementary Material & Methods section.
References
 1. Berthet, J., Rall, T. W. & Sutherland, E. W. The relationship of epinephrine and glucagon to liver phosphorylase. IV. Effect of 
epinephrine and glucagon on the reactivation of phosphorylase in liver homogenates. The Journal of biological chemistry 224, 
463–475 (1957).
 2. Rui, L. Energy metabolism in the liver. Comprehensive Physiology 4, 177–197, https://doi.org/10.1002/cphy.c130024 (2014).
 3. Servillo, G., Della Fazia, M. A. & Sassone-Corsi, P. Transcription factor CREM coordinates the timing of hepatocyte proliferation in 
the regenerating liver. Genes Dev 12, 3639–3643 (1998).
 4. Sequera, C., Manzano, S., Guerrero, C. & Porras, A. How Rap and its GEFs control liver physiology and cancer development. C3G 
alterations in human hepatocarcinoma. Hepat Oncol 5, HEP05, https://doi.org/10.2217/hep-2017-0026 (2018).
 5. de Rooij, J. et al. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature 396, 474–477, https://
doi.org/10.1038/24884 (1998).
 6. Kawasaki, H. et al. A family of cAMP-binding proteins that directly activate Rap1. Science 282, 2275–2279 (1998).
 7. Schmidt, M., Dekker, F. J. & Maarsingh, H. Exchange protein directly activated by cAMP (epac): a multidomain cAMP mediator in 
the regulation of diverse biological functions. Pharmacological reviews 65, 670–709, https://doi.org/10.1124/pr.110.003707 (2013).
 8. Hoivik, E. A. et al. DNA methylation of alternative promoters directs tissue specific expression of Epac2 isoforms. PloS one 8, 
e67925, https://doi.org/10.1371/journal.pone.0067925 (2013).
 9. Niimura, M. et al. Critical role of the N-terminal cyclic AMP-binding domain of Epac2 in its subcellular localization and function. 
Journal of cellular physiology 219, 652–658, https://doi.org/10.1002/jcp.21709 (2009).
 10. Ueno, H. et al. Characterization of the gene EPAC2: structure, chromosomal localization, tissue expression, and identification of the 
liver-specific isoform. Genomics 78, 91–98, https://doi.org/10.1006/geno.2001.6641 (2001).
 11. Alenkvist, I., Gandasi, N. R., Barg, S. & Tengholm, A. Recruitment of Epac2A to Insulin Granule Docking Sites Regulates Priming 
for Exocytosis. Diabetes 66, 2610–2622, https://doi.org/10.2337/db17-0050 (2017).
 12. Sugawara, K., Shibasaki, T., Takahashi, H. & Seino, S. Structure and functional roles of Epac2 (Rapgef4). Gene 575, 577–583, https://
doi.org/10.1016/j.gene.2015.09.029 (2016).
 13. Yokoyama, U. et al. The cyclic AMP effector Epac integrates pro- and anti-fibrotic signals. Proc Natl Acad Sci USA 105, 6386–6391, 
https://doi.org/10.1073/pnas.0801490105 (2008).
 14. Banales, J. M. et al. The cAMP effectors Epac and protein kinase a (PKA) are involved in the hepatic cystogenesis of an animal model 
of autosomal recessive polycystic kidney disease (ARPKD). Hepatology 49, 160–174, https://doi.org/10.1002/hep.22636 (2009).
 15. Fu, D., Wakabayashi, Y., Lippincott-Schwartz, J. & Arias, I. M. Bile acid stimulates hepatocyte polarization through a cAMP-Epac-
MEK-LKB1-AMPK pathway. Proceedings of the National Academy of Sciences of the United States of America 108, 1403–1408, https://
doi.org/10.1073/pnas.1018376108 (2011).
 16. Cyphert, H. A., Alonge, K. M., Ippagunta, S. M. & Hillgartner, F. B. Glucagon stimulates hepatic FGF21 secretion through a PKA- 
and EPAC-dependent posttranscriptional mechanism. PloS one 9, e94996, https://doi.org/10.1371/journal.pone.0094996 (2014).
 17. Schippers, M. et al. Upregulation of Epac-1 in Hepatic Stellate Cells by Prostaglandin E2 in Liver Fibrosis Is Associated with Reduced 
Fibrogenesis. J Pharmacol Exp Ther 363, 126–135, https://doi.org/10.1124/jpet.117.241646 (2017).
 18. Insel, P. A. et al. cAMP and Epac in the regulation of tissue fibrosis. Br J Pharmacol 166, 447–456, https://doi.org/10.1111/j.1476-
5381.2012.01847.x (2012).
 19. Enserink, J. M. et al. A novel Epac-specific cAMP analogue demonstrates independent regulation of Rap1 and ERK. Nature cell 
biology 4, 901–906, https://doi.org/10.1038/ncb874 (2002).
 20. Herfindal, L. et al. Off-target effect of the Epac agonist 8-pCPT-2′-O-Me-cAMP on P2Y12 receptors in blood platelets. Biochemical 
and biophysical research communications 437, 603–608, https://doi.org/10.1016/j.bbrc.2013.07.007 (2013).
1 5Scientific RepoRtS |         (2019) 9:13789  | https://doi.org/10.1038/s41598-019-50219-8
www.nature.com/scientificreportswww.nature.com/scientificreports/
 21. Herfindal, L. et al. Introduction of aromatic ring-containing substituents in cyclic nucleotides is associated with inhibition of toxin 
uptake by the hepatocyte transporters OATP 1B1 and 1B3. PloS one 9, e94926, https://doi.org/10.1371/journal.pone.0094926 (2014).
 22. Poppe, H. et al. Cyclic nucleotide analogs as probes of signaling pathways. Nature methods 5, 277–278, https://doi.org/10.1038/
nmeth0408-277 (2008).
 23. Yan, J. et al. Enhanced leptin sensitivity, reduced adiposity, and improved glucose homeostasis in mice lacking exchange protein 
directly activated by cyclic AMP isoform 1. Molecular and cellular biology 33, 918–926, https://doi.org/10.1128/MCB.01227-12 
(2013).
 24. Almahariq, M., Mei, F. C. & Cheng, X. Cyclic AMP sensor EPAC proteins and energy homeostasis. Trends in endocrinology and 
metabolism: TEM 25, 60–71, https://doi.org/10.1016/j.tem.2013.10.004 (2014).
 25. Vliem, M. J. et al. 8-pCPT-2′-O-Me-cAMP-AM: an improved Epac-selective cAMP analogue. Chembiochem: a European journal of 
chemical biology 9, 2052–2054, https://doi.org/10.1002/cbic.200800216 (2008).
 26. Schwede, F. et al. Structure-guided design of selective Epac1 and Epac2 agonists. PLoS Biol 13, e1002038, https://doi.org/10.1371/
journal.pbio.1002038 (2015).
 27. Huang, J. & Rudnick, D. A. Elucidating the metabolic regulation of liver regeneration. The American journal of pathology 184, 
309–321, https://doi.org/10.1016/j.ajpath.2013.04.034 (2014).
 28. Rudnick, D. A., Perlmutter, D. H. & Muglia, L. J. Prostaglandins are required for CREB activation and cellular proliferation during 
liver regeneration. Proceedings of the National Academy of Sciences of the United States of America 98, 8885–8890, https://doi.
org/10.1073/pnas.151217998 (2001).
 29. Miyaoka, Y. et al. Hypertrophy and unconventional cell division of hepatocytes underlie liver regeneration. Current biology: CB 22, 
1166–1175, https://doi.org/10.1016/j.cub.2012.05.016 (2012).
 30. Liu, M. & Chen, P. Proliferationinhibiting pathways in liver regeneration (Review). Mol Med Rep 16, 23–35, https://doi.org/10.3892/
mmr.2017.6613 (2017).
 31. Tan, Q. et al. The Role of IL-1 Family Members and Kupffer Cells in Liver Regeneration. Biomed Res Int 2016, 6495793, https://doi.
org/10.1155/2016/6495793 (2016).
 32. Shteyer, E., Liao, Y., Muglia, L. J., Hruz, P. W. & Rudnick, D. A. Disruption of hepatic adipogenesis is associated with impaired liver 
regeneration in mice. Hepatology 40, 1322–1332, https://doi.org/10.1002/hep.20462 (2004).
 33. Kai, A. K. et al. Exchange protein activated by cAMP 1 (Epac1)-deficient mice develop beta-cell dysfunction and metabolic 
syndrome. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 27, 4122–4135, https://
doi.org/10.1096/fj.13-230433 (2013).
 34. Newberry, E. P. et al. Altered hepatic triglyceride content after partial hepatectomy without impaired liver regeneration in multiple 
murine genetic models. Hepatology 48, 1097–1105, https://doi.org/10.1002/hep.22473 (2008).
 35. Peng, J. et al. Enhanced Liver Regeneration After Partial Hepatectomy in Sterol Regulatory Element-Binding Protein (SREBP)-1c-
Null Mice is Associated with Increased Hepatocellular Cholesterol Availability. Cell Physiol Biochem 47, 784–799, https://doi.
org/10.1159/000490030 (2018).
 36. Bracht, T. et al. Proteome analysis of a hepatocyte-specific BIRC5 (survivin)-knockout mouse model during liver regeneration. 
Journal of proteome research 13, 2771–2782, https://doi.org/10.1021/pr401188r (2014).
 37. Zhang, X. et al. Ablation of cytochrome P450 omega-hydroxylase 4A14 gene attenuates hepatic steatosis and fibrosis. Proceedings of 
the National Academy of Sciences of the United States of America 114, 3181–3185, https://doi.org/10.1073/pnas.1700172114 (2017).
 38. Jungermann, K. & Kietzmann, T. Oxygen: modulator of metabolic zonation and disease of the liver. Hepatology 31, 255–260, https://
doi.org/10.1002/hep.510310201 (2000).
 39. Rakhshandehroo, M., Knoch, B., Muller, M. & Kersten, S. Peroxisome proliferator-activated receptor alpha target genes. PPAR 
research 2010, https://doi.org/10.1155/2010/612089 (2010).
 40. Huang, W. et al. Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration. Science 312, 233–236, 
https://doi.org/10.1126/science.1121435 (2006).
 41. Cheema, S. K. & Agellon, L. B. The murine and human cholesterol 7alpha-hydroxylase gene promoters are differentially responsive 
to regulation by fatty acids mediated via peroxisome proliferator-activated receptor alpha. The Journal of biological chemistry 275, 
12530–12536 (2000).
 42. Kliewer, S. A. & Mangelsdorf, D. J. Bile Acids as Hormones: The FXR-FGF15/19 Pathway. Dig Dis 33, 327–331, https://doi.
org/10.1159/000371670 (2015).
 43. Valsecchi, F., Ramos-Espiritu, L. S., Buck, J., Levin, L. R. & Manfredi, G. cAMP and mitochondria. Physiology (Bethesda) 28, 
199–209, https://doi.org/10.1152/physiol.00004.2013 (2013).
 44. Chen, J. et al. Identification of novel modulators of mitochondrial function by a genome-wide RNAi screen in Drosophila 
melanogaster. Genome Res 18, 123–136, https://doi.org/10.1101/gr.6940108 (2008).
 45. Qiao, J., Mei, F. C., Popov, V. L., Vergara, L. A. & Cheng, X. Cell cycle-dependent subcellular localization of exchange factor directly 
activated by cAMP. J Biol Chem 277, 26581–26586, https://doi.org/10.1074/jbc.M203571200 (2002).
 46. DiPilato, L. M., Cheng, X. & Zhang, J. Fluorescent indicators of cAMP and Epac activation reveal differential dynamics of cAMP 
signaling within discrete subcellular compartments. Proc Natl Acad Sci USA 101, 16513–16518, https://doi.org/10.1073/
pnas.0405973101 (2004).
 47. Tao, Y., Wang, M., Chen, E. & Tang, H. Liver Regeneration: Analysis of the Main Relevant Signaling Molecules. Mediators Inflamm 
2017, 4256352, https://doi.org/10.1155/2017/4256352 (2017).
 48. Yin, C., Evason, K. J., Asahina, K. & Stainier, D. Y. Hepatic stellate cells in liver development, regeneration, and cancer. J Clin Invest 
123, 1902–1910, https://doi.org/10.1172/JCI66369 (2013).
 49. Cheng, Z. et al. Ten paths of PKA signaling pathway regulate hepatocyte proliferation in rat liver regeneration. Genes & Genomics 
34, 391–399, https://doi.org/10.1007/s13258-011-0195-x (2012).
 50. Diehl, A. M., Yang, S. Q., Wolfgang, D. & Wand, G. Differential expression of guanine nucleotide-binding proteins enhances cAMP 
synthesis in regenerating rat liver. The Journal of clinical investigation 89, 1706–1712, https://doi.org/10.1172/JCI115771 (1992).
 51. Servillo, G., Della Fazia, M. A. & Sassone-Corsi, P. Coupling cAMP signaling to transcription in the liver: pivotal role of CREB and 
CREM. Experimental cell research 275, 143–154, https://doi.org/10.1006/excr.2002.5491 (2002).
 52. Liu, W. H. et al. Hepatocyte proliferation during liver regeneration is impaired in mice with methionine diet-induced 
hyperhomocysteinemia. The American journal of pathology 177, 2357–2365, https://doi.org/10.2353/ajpath.2010.091131 (2010).
 53. Groeneveld, D. et al. Intrahepatic fibrin(ogen) deposition drives liver regeneration after partial hepatectomy in mice and humans. 
Blood 133, 1245–1256, https://doi.org/10.1182/blood-2018-08-869057 (2019).
 54. Kirschbaum, M. et al. Transient von Willebrand factor-mediated platelet influx stimulates liver regeneration after partial 
hepatectomy in mice. Liver Int 37, 1731–1737, https://doi.org/10.1111/liv.13386 (2017).
 55. Lesurtel, M. et al. Platelet-derived serotonin mediates liver regeneration. Science 312, 104–107, https://doi.org/10.1126/
science.1123842 (2006).
 56. Nygaard, G. et al. Epac1-deficient mice have bleeding phenotype and thrombocytes with decreased GPIbbeta expression. Sci Rep 7, 
8725, https://doi.org/10.1038/s41598-017-08975-y (2017).
 57. Robichaux, W. G. 3rd. & Cheng, X. Intracellular cAMP Sensor EPAC: Physiology, Pathophysiology, and Therapeutics Development. 
Physiol Rev 98, 919–1053, https://doi.org/10.1152/physrev.00025.2017 (2018).
1 6Scientific RepoRtS |         (2019) 9:13789  | https://doi.org/10.1038/s41598-019-50219-8
www.nature.com/scientificreportswww.nature.com/scientificreports/
 58. Elchaninov, A. V. et al. Dynamics of macrophage populations of the liver after subtotal hepatectomy in rats. BMC Immunol 19, 23, 
https://doi.org/10.1186/s12865-018-0260-1 (2018).
 59. Eroglu, A. et al. Effect of granulocyte-macrophage colony-stimulating factor on hepatic regeneration after 70% hepatectomy in 
normal and cirrhotic rats. HPB (Oxford) 4, 67–73, https://doi.org/10.1080/136518202760378425 (2002).
 60. Michalopoulos, G. K. Hepatostat: Liver regeneration and normal liver tissue maintenance. Hepatology 65, 1384–1392, https://doi.
org/10.1002/hep.28988 (2017).
 61. Hunt, A. N. et al. Hepatic Steatosis Accompanies Pulmonary Alveolar Proteinosis. Am J Respir Cell Mol Biol 57, 448–458, https://doi.
org/10.1165/rcmb.2016-0242OC (2017).
 62. Dixon, L. J., Barnes, M., Tang, H., Pritchard, M. T. & Nagy, L. E. Kupffer cells in the liver. Compr Physiol 3, 785–797, https://doi.
org/10.1002/cphy.c120026 (2013).
 63. Almahariq, M., Mei, F. C. & Cheng, X. The pleiotropic role of exchange protein directly activated by cAMP 1 (EPAC1) in cancer: 
implications for therapeutic intervention. Acta biochimica et biophysica Sinica 48, 75–81, https://doi.org/10.1093/abbs/gmv115 
(2016).
 64. Michalopoulos, G. K. Liver regeneration. J Cell Physiol 213, 286–300, https://doi.org/10.1002/jcp.21172 (2007).
 65. Zou, Y. et al. Four waves of hepatocyte proliferation linked with three waves of hepatic fat accumulation during partial hepatectomy-
induced liver regeneration. PLoS One 7, e30675, https://doi.org/10.1371/journal.pone.0030675 (2012).
 66. Rai, R. M. et al. Kupffer cell depletion abolishes induction of interleukin-10 and permits sustained overexpression of tumor necrosis 
factor alpha messenger RNA in the regenerating rat liver. Hepatology 25, 889–895, https://doi.org/10.1002/hep.510250417 (1997).
 67. Garcia-Arcos, I. et al. Lipid analysis reveals quiescent and regenerating liver-specific populations of lipid droplets. Lipids 45, 
1101–1108, https://doi.org/10.1007/s11745-010-3492-2 (2010).
 68. Pauta, M. et al. Impaired liver regeneration in Ldlr-/- mice is associated with an altered hepatic profile of cytokines, growth factors, 
and lipids. Journal of hepatology 59, 731–737, https://doi.org/10.1016/j.jhep.2013.05.026 (2013).
 69. Hardwick, J. P. Cytochrome P450 omega hydroxylase (CYP4) function in fatty acid metabolism and metabolic diseases. Biochemical 
pharmacology 75, 2263–2275, https://doi.org/10.1016/j.bcp.2008.03.004 (2008).
 70. Chatuphonprasert, W., Nemoto, N., Sakuma, T. & Jarukamjorn, K. Modulations of cytochrome P450 expression in diabetic mice by 
berberine. Chem Biol Interact 196, 23–29, https://doi.org/10.1016/j.cbi.2012.01.006 (2012).
 71. Yoshinari, K., Takagi, S., Sugatani, J. & Miwa, M. Changes in the expression of cytochromes P450 and nuclear receptors in the liver 
of genetically diabetic db/db mice. Biol Pharm Bull 29, 1634–1638 (2006).
 72. Enriquez, A., Leclercq, I., Farrell, G. C. & Robertson, G. Altered expression of hepatic CYP2E1 and CYP4A in obese, diabetic ob/ob 
mice, and fa/fa Zucker rats. Biochemical and biophysical research communications 255, 300–306, https://doi.org/10.1006/
bbrc.1999.0202 (1999).
 73. Glen, J., Floros, L., Day, C., Pryke, R. & Guideline Development, G. Non-alcoholic fatty liver disease (NAFLD): summary of NICE 
guidance. Bmj 354, i4428, https://doi.org/10.1136/bmj.i4428 (2016).
 74. Hwang, M. et al. Epac2a-null mice exhibit obesity-prone nature more susceptible to leptin resistance. International journal of obesity 
41, 279–288, https://doi.org/10.1038/ijo.2016.208 (2017).
 75. Lee, K. et al. Involvement of cAMP-guanine nucleotide exchange factor II in hippocampal long-term depression and behavioral 
flexibility. Molecular brain 8, 38, https://doi.org/10.1186/s13041-015-0130-1 (2015).
 76. Shibasaki, T. et al. Essential role of Epac2/Rap1 signaling in regulation of insulin granule dynamics by cAMP. Proceedings of the 
National Academy of Sciences of the United States of America 104, 19333–19338, https://doi.org/10.1073/pnas.0707054104 (2007).
 77. Suzuki, S. et al. Differential roles of Epac in regulating cell death in neuronal and myocardial cells. The Journal of biological chemistry 
285, 24248–24259, https://doi.org/10.1074/jbc.M109.094581 (2010).
 78. Yang, Y. et al. EPAC null mutation impairs learning and social interactions via aberrant regulation of miR-124 and Zif268 translation. 
Neuron 73, 774–788, https://doi.org/10.1016/j.neuron.2012.02.003 (2012).
 79. Song, W. J., Mondal, P., Li, Y., Lee, S. E. & Hussain, M. A. Pancreatic beta-cell response to increased metabolic demand and to 
pharmacologic secretagogues requires EPAC2A. Diabetes 62, 2796–2807, https://doi.org/10.2337/db12-1394 (2013).
 80. Okumura, S. et al. Epac1-dependent phospholamban phosphorylation mediates the cardiac response to stresses. The Journal of 
clinical investigation 124, 2785–2801, https://doi.org/10.1172/JCI64784 (2014).
 81. Kopperud, R. K. et al. Increased microvascular permeability in mice lacking Epac1 (Rapgef3). Acta Physiol (Oxf) 219, 441–452, 
https://doi.org/10.1111/apha.12697 (2017).
 82. Edland, F. et al. Long-term consumption of an obesogenic high fat diet prior to ischemia-reperfusion mediates cardioprotection via 
Epac1-dependent signaling. Nutrition & metabolism 13, 87, https://doi.org/10.1186/s12986-016-0147-1 (2016).
 83. Aesoy, R. et al. Deletion of exchange proteins directly activated by cAMP (Epac) causes defects in hippocampal signaling in female 
mice. PloS one 13, e0200935, https://doi.org/10.1371/journal.pone.0200935 (2018).
 84. Takahashi, H. et al. Role of Epac2A/Rap1 signaling in interplay between incretin and sulfonylurea in insulin secretion. Diabetes 64, 
1262–1272, https://doi.org/10.2337/db14-0576 (2015).
 85. Barker, G. et al. The Potential of a Novel Class of EPAC-Selective Agonists to Combat Cardiovascular Inflammation. J Cardiovasc 
Dev Dis 4, https://doi.org/10.3390/jcdd4040022 (2017).
 86. Mitchell, C. & Willenbring, H. A reproducible and well-tolerated method for 2/3 partial hepatectomy in mice. Nature protocols 3, 
1167–1170, https://doi.org/10.1038/nprot.2008.80 (2008).
 87. Henderson, N. C. et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proceedings of the National Academy of 
Sciences of the United States of America 103, 5060–5065, https://doi.org/10.1073/pnas.0511167103 (2006).
 88. Lynch, R. W. et al. An efficient method to isolate Kupffer cells eliminating endothelial cell contamination and selective bias. Journal 
of leukocyte biology 104, 579–586, https://doi.org/10.1002/JLB.1TA0517-169R (2018).
 89. Gubern, C. et al. Validation of housekeeping genes for quantitative real-time PCR in in-vivo and in-vitro models of cerebral 
ischaemia. BMC molecular biology 10, 57, https://doi.org/10.1186/1471-2199-10-57 (2009).
 90. Kosir, R. et al. Determination of reference genes for circadian studies in different tissues and mouse strains. BMC molecular biology 
11, 60, https://doi.org/10.1186/1471-2199-11-60 (2010).
 91. Pernot, F., Dorandeu, F., Beaup, C. & Peinnequin, A. Selection of reference genes for real-time quantitative reverse transcription-
polymerase chain reaction in hippocampal structure in a murine model of temporal lobe epilepsy with focal seizures. Journal of 
neuroscience research 88, 1000–1008, https://doi.org/10.1002/jnr.22282 (2010).
 92. Wisniewski, J. R., Zougman, A., Nagaraj, N. & Mann, M. Universal sample preparation method for proteome analysis. Nature 
methods 6, 359–362, https://doi.org/10.1038/nmeth.1322 (2009).
 93. Hernandez-Valladares, M. et al. Reliable FASP-based procedures for optimal quantitative proteomic and phosphoproteomic analysis 
on samples from acute myeloid leukemia patients. Biological procedures online 18, 13, https://doi.org/10.1186/s12575-016-0043-0 
(2016).
 94. Scholz, C. et al. Avoiding abundance bias in the functional annotation of post-translationally modified proteins. Nature methods 12, 
1003–1004, https://doi.org/10.1038/nmeth.3621 (2015).
 95. Vizcaino, J. A. et al. 2016 update of the PRIDE database and its related tools. Nucleic acids research 44, D447–456, https://doi.
org/10.1093/nar/gkv1145 (2016).
 96. Vizcaino, J. A. et al. ProteomeXchange provides globally coordinated proteomics data submission and dissemination. Nature 
biotechnology 32, 223–226, https://doi.org/10.1038/nbt.2839 (2014).
17Scientific RepoRtS |         (2019) 9:13789  | https://doi.org/10.1038/s41598-019-50219-8
www.nature.com/scientificreportswww.nature.com/scientificreports/
Acknowledgements
We thank Dr. Joël Maillet, BioTek Instruments GmbH, Kjellfrid Haukanes and Nina Lied Larsen (UiB) for 
excellent technical assistance. This work was supported by The Research Council of Norway (Grant no. 183451/
S10; MB) and The Regional Health Authorities, Western Norway (Grant no. 911979; SOD).
Author contributions
K.S.A., L.P. Planning and execution of experiments, preparation of manuscript; R.A., H.M., E.A., I.K.N.P., 
L.H., R.D., S.J., R.K.B., N.H., F.S. Planning and execution of experiments; S.O.D. Planning and financing study, 
preparing manuscript; M.B. Coordinating, planning and financing study, preparing manuscript. All authors read 
and approved the final manuscript.
Additional information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-50219-8.
Competing Interests: The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2019
